Behavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice

dc.contributor.authorGriñán Ferré, Christian
dc.contributor.authorVasilopoulou, Foteini
dc.contributor.authorAbás Prades, Sònia
dc.contributor.authorRodríguez-Arévalo, Sergio
dc.contributor.authorBagan Polonio, Andrea
dc.contributor.authorSureda, Francesc X.
dc.contributor.authorPérez, Belén
dc.contributor.authorCallado, Luis F.
dc.contributor.authorGarcía-Sevilla, Jesús A.
dc.contributor.authorGarcía-Fuster, M. Julia
dc.contributor.authorEscolano Mirón, Carmen
dc.contributor.authorPallàs i Llibería, Mercè, 1964-
dc.date.accessioned2019-09-23T11:06:39Z
dc.date.issued2018-11-20
dc.date.updated2019-09-23T11:06:40Z
dc.description.abstractAs populations increase their life expectancy, age-related neurodegenerative disorders such as Alzheimer's disease have become more common. I2-Imidazoline receptors (I2-IR) are widely distributed in the central nervous system, and dysregulation of I2-IR in patients with neurodegenerative diseases has been reported, suggesting their implication in cognitive impairment. This evidence indicates that high-affinity selective I2-IR ligands potentially contribute to the delay of neurodegeneration. In vivo studies in the female senescence accelerated mouse-prone 8 mice have shown that treatment with I2-IR ligands, MCR5 and MCR9, produce beneficial effects in behavior and cognition. Changes in molecular pathways implicated in oxidative stress, inflammation, synaptic plasticity, and apoptotic cell death were also studied. Furthermore, treatments with these I2-IR ligands diminished the amyloid precursor protein processing pathway and increased Aβ degrading enzymes in the hippocampus of SAMP8 mice. These results collectively demonstrate the neuroprotective role of these new I2-IR ligands in a mouse model of brain aging through specific pathways and suggest their potential as therapeutic agents in brain disorders and age-related neurodegenerative diseases. Keywords Imidazoline I2 receptors (2-imidazolin-4-yl)phosphonates Behavior Cognition Neurodegeneration Neuroprotection Aging
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec682992
dc.identifier.issn1933-7213
dc.identifier.pmid30460457
dc.identifier.urihttps://hdl.handle.net/2445/140738
dc.language.isoeng
dc.publisherSpringer Verlag
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1007/s13311-018-00681-5
dc.relation.ispartofNeurotherapeutics, 2018
dc.relation.urihttps://doi.org/10.1007/s13311-018-00681-5
dc.rights(c) American Society for Experimental NeuroTherapeutics, 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.classificationMalalties neurodegeneratives
dc.subject.classificationEnvelliment
dc.subject.otherAlzheimer's disease
dc.subject.otherNeurodegenerative Diseases
dc.subject.otherAging
dc.titleBehavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
682992.pdf
Mida:
7.23 MB
Format:
Adobe Portable Document Format

Paquet de llicències

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
license.txt
Mida:
1.71 KB
Format:
Item-specific license agreed upon to submission
Descripció: